Evidence map›Paper›PMID 38877522›Full record

ArticleHarm reduction journal2024

An urgent need for community lot testing of lateral flow fentanyl test strips marketed for harm reduction in Northern America.

Marya Lieberman, Adina Badea, Charlie Desnoyers, Kathleen Hayes, Ju Nyeong Park

Abstract read
In one paragraph

Article in Harm reduction journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Interpol review of forensic drug chemistry, 2022-2025.Forensic science international. Synergy · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marya LiebermanUniversity of Notre Dame, Notre Dame, IN, USA. mlieberm@nd.edu.ORCID 0000-0003-3968-8044
Adina BadeaLifespan Academic Medical Center, Providence, RI, USA.ORCID 0000-0002-7077-2810
Charlie DesnoyersUniversity of Notre Dame, Notre Dame, IN, USA.ORCID 0000-0001-8285-0081
Kathleen HayesUniversity of Notre Dame, Notre Dame, IN, USA.ORCID 0000-0003-1217-0050
Ju Nyeong ParkBrown University, Providence, RI, USA.ORCID 0000-0001-6490-9887

Funding

Project 4: Neonatal Abstinence Syndrome (NAS): Fetus to First YearsP20GM125507 · NIGMS · RHODE ISLAND HOSPITAL · PI Ju Nyeong Park · 2018 to 2026
$23.4M
National Science Foundation IIP-2016516NIGMS NIH HHS P20 GM125507NIH HHS P20GM125507University of Notre Dame Berthiaume Institute for Precision Health, Emerging Opportunities Fund, Blockchain Fund
6 · The paper itself

Abstract

backgroundFentanyl test strips (FTS) are lateral flow immunoassay strips designed for detection of ng/mL levels of fentanyl in urine. In 2021, the US Centers for Disease Control and the Substance Abuse and Mental Health Administration stated that federal funds could be used for procurement of FTS for harm reduction strategies approved by the government such as drug checking. The market for FTS has expanded rapidly in the US and Canada. However, there is no regulatory oversight by either government to ensure proper function of FTS that are being marketed for drug checking. MAIN BODY: Many brands of FTS have rapidly entered the harm reduction market, creating concerns about the reproducibility and accuracy of their performance from brand to brand and lot to lot. Some examples are provided in this Comment. Similar problems with product quality were observed in the mid 2000's when lateral flow immunoassays for malaria were funded in many countries and again in 2020, when COVID-19 tests were in huge demand. The combination of high demand and low levels of regulation and enforcement led some manufacturers to join the goldrush without adequate field testing or quality assurance. We argue that the harm reduction community urgently needs to set a lot checking program in place. A set of simple protocols for conducting the tests and communicating the results have been developed, and are described in the following Perspectives paper in this issue.

conclusionIn the absence of governmental regulation and enforcement, the harm reduction community should implement a FTS lot checking program. Based on previous experience with the malaria diagnostic lot checking program, this inexpensive effort could identify products that are not suitable for harm reduction applications and provide valuable feedback to manufacturers. Dissemination of the results will help harm reduction organizations to ensure that FTS they use for drug checking are fit for the purpose.

Indexed as

FentanylHarm ReductionReagent StripsAnalgesics, OpioidCOVID-19HumansImmunoassayNorth AmericaReproducibility of ResultsSubstance Abuse DetectionAnalgesics, OpioidFentanylReagent StripsDrug supplyFentanyl test stripsValidation

Identifiers

PMID38877522
PMCPMC11179324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.